The reason why NFIL3 differently expressed in the response of anti‐PD1 therapy in melanoma and renal cell carcinoma may be that NFIL3 expression is associated with infiltration of different immune cells in these two cancer types. This evidence concerns the gene NFIL3 and melanoma.